A company developing a means to edit RNA has raised more than $30 million in a venture capital funding round.
Seattle-based Shape Therapeutics, or ShapeTx, said that it had raised a $35.5 million Series A financing, led by New Enterprise Associates and with participation from CureDuchenne Ventures. The company said it plans to use the money to build up its intellectual property, hire scientists and advance its RNA and protein-targeting technology, which it describes as being aimed at curing genetic diseases.